<DOC>
	<DOCNO>NCT02711553</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety ramucirumab merestinib placebo plus cisplatin gemcitabine participant advance metastatic biliary tract cancer .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Merestinib ( LY2801653 ) Advanced Metastatic Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Have Eastern Cooperative Oncology Group performance status 0 1 . Have histologically cytologically confirm diagnosis nonresectable , recurrent , metastatic biliary tract adenocarcinoma ( intrahepatic extrahepatic cholangiocarcinoma , gallbladder cancer , Ampulla Vater ) . Have measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) . Have adequate biliary drainage . Have adequate organ function . Males female sterile , postmenopausal , compliant highly effective contraceptive method . Female participant childbearing potential must negative serum pregnancy test within 7 day prior first dose . Are willing provide blood/serum/plasma tumor tissue sample research purpose . Submission blood/serum/plasma tumor tissue sample mandatory participation study , unless restrict per local regulation . Previous systemic therapy locally advance metastatic disease allow . Have history current hepatic encephalopathy grade , ascites Grade &gt; 1 , cirrhosis ChildPugh Stage B high . Have ongoing recent ( ≤6 month ) hepatorenal syndrome . Have major surgical procedure significant traumatic injury include nonhealing wound , peptic ulcer , bone fracture ≤28 day prior randomization . Anticipate major surgical procedure course study . Has document brain metastasis , leptomeningeal disease , uncontrolled spinal cord compression . Within 6 month prior randomization , arterial thrombotic event , include myocardial infarction , unstable angina , cerebrovascular accident , transient ischemic attack . Have uncontrolled arterial hypertension systolic blood pressure ≥150 diastolic blood pressure ≥90 millimeter mercury ( mm Hg ) despite standard medical management . Have previous malignancy within 5 year study entry concurrent malignancy . Have history gastrointestinal perforation and/or fistula within 6 month prior randomization . Have know allergy hypersensitivity reaction treatment component . Have history uncontrolled hereditary acquire thrombotic disorder . Have uncontrolled metabolic disorder nonmalignant organ systemic disease secondary effect cancer induce high medical risk and/or make assessment survival uncertain . Have mixed hepatocellular biliary tract cancer histology . Have correct QT interval &gt; 470 millisecond calculate Fredericia equation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>